Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice.
High-dose opioids
efficacy
pain
quality of life
survival
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
13
07
2022
accepted:
13
09
2022
entrez:
21
10
2022
pubmed:
22
10
2022
medline:
22
10
2022
Statut:
ppublish
Résumé
Pain is a common symptom among cancer patients and directly affects their prognosis. As the leading drug for pain management, opioids are widely prescribed. So it is necessary to get people a correct understanding and application of opioids. In order to examine whether the use of high-dose opioids might affect survival and quality of life, this retrospective cohort study was performed to explore the outcomes of patients receiving high-dose opioids for pain management in a first-class tertiary hospital in China. We retrospectively searched medical records of inpatients and outpatients with pain who were treated with opioids in The First Affiliated Hospital, Zhejiang University School of Medicine from July to December 2021. Forty-three cases who were treated with high-dose opioids meeting inclusion criteria. Among these patients, 37 had cancer pain and 6 had neuropathic pain. All patients had regular follow-up when readmission until to April 7, 2022. Medical records of patients on high-dose opioids (equivalent to morphine ≥300 mg/d) was collected, including numerical rating scale (NRS), Karnofsky performance score (KPS), survival and adverse drug reactions (ADRs). Pain relief, quality of life, survival, and ADRs of patients after pain treatment were analyzed and evaluated. The NRS score was significantly reduced and pain was relieved after high-dose opioid treatment. The before and after average NRS score of cancer pain was 5.2±1.6 Multimodal high-dose opioid pain treatments are important approaches to effectively relieve moderate to severe pain and improve the quality of life of patients. This study provides a clinical basis for future pain treatment with high-dose opioids.
Sections du résumé
Background
UNASSIGNED
Pain is a common symptom among cancer patients and directly affects their prognosis. As the leading drug for pain management, opioids are widely prescribed. So it is necessary to get people a correct understanding and application of opioids. In order to examine whether the use of high-dose opioids might affect survival and quality of life, this retrospective cohort study was performed to explore the outcomes of patients receiving high-dose opioids for pain management in a first-class tertiary hospital in China.
Methods
UNASSIGNED
We retrospectively searched medical records of inpatients and outpatients with pain who were treated with opioids in The First Affiliated Hospital, Zhejiang University School of Medicine from July to December 2021. Forty-three cases who were treated with high-dose opioids meeting inclusion criteria. Among these patients, 37 had cancer pain and 6 had neuropathic pain. All patients had regular follow-up when readmission until to April 7, 2022. Medical records of patients on high-dose opioids (equivalent to morphine ≥300 mg/d) was collected, including numerical rating scale (NRS), Karnofsky performance score (KPS), survival and adverse drug reactions (ADRs). Pain relief, quality of life, survival, and ADRs of patients after pain treatment were analyzed and evaluated.
Results
UNASSIGNED
The NRS score was significantly reduced and pain was relieved after high-dose opioid treatment. The before and after average NRS score of cancer pain was 5.2±1.6
Conclusions
UNASSIGNED
Multimodal high-dose opioid pain treatments are important approaches to effectively relieve moderate to severe pain and improve the quality of life of patients. This study provides a clinical basis for future pain treatment with high-dose opioids.
Identifiants
pubmed: 36267754
doi: 10.21037/atm-22-4242
pii: atm-10-18-998
pmc: PMC9577752
doi:
Types de publication
Journal Article
Langues
eng
Pagination
998Informations de copyright
2022 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-4242/coif). MS reports that he received collaborative and non-collaborative research funding from Shionogi & Co., Ltd., Nippon Zoki Pharmaceticals, Heartfelt Inc., Nipro, and Eisai Co., Ltd; payments for his educational presentations from Daiichi Sankyo Inc. and GSK plc. The other authors have no conflicts of interest to declare.
Références
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):11-7
pubmed: 26702846
Pain Med. 2013 Dec;14(12):1866-72
pubmed: 24010556
Eur J Clin Pharmacol. 2020 Mar;76(3):393-402
pubmed: 31865411
Med Sci Monit. 2018 Sep 19;24:6750-6755
pubmed: 30229751
J Neurosci Res. 2022 Jan;100(1):362-372
pubmed: 33174646
Eur J Pain. 2021 May;25(5):949-968
pubmed: 33655607
J Pain Symptom Manage. 2017 Sep;54(3):280-288
pubmed: 28711751
Cancer. 2004 Sep 15;101(6):1473-7
pubmed: 15368335
Pain. 2015 Nov;156(11):2152-2163
pubmed: 26207652
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Pharmacol Ther. 2022 May;233:108019
pubmed: 34637841
Ther Clin Risk Manag. 2008 Aug;4(4):665-72
pubmed: 19209246
Med Sci Monit. 2018 Nov 01;24:7809-7819
pubmed: 30382075
J Pain Palliat Care Pharmacother. 2006;20(4):33-9
pubmed: 17182504
Libyan J Med. 2020 Dec;15(1):1730550
pubmed: 32066339
Cancer. 2021 Sep 1;127(17):3239-3245
pubmed: 33905550
Intern Med J. 2005 Sep;35(9):512-7
pubmed: 16105151
J Natl Compr Canc Netw. 2019 Aug 1;17(8):977-1007
pubmed: 31390582
J Pain Symptom Manage. 2006 Dec;32(6):532-40
pubmed: 17157755
Eur J Pain. 2010 Apr;14(4):372-9
pubmed: 19664944